With Biomagnetic Solutions next-generation cell selection and bioseparation technology company structured around providing cutting-edge ferrofluids (nano magnetic liquids) and novel multi-parameter magnetic separator systems to the life sciences. BMS developed clinical-grade ferrofluids & clinical-scale immuno-magnetic cell separation platforms for: CAR-T cell therapies and CD34+ stem cell isolations for gene therapy (GT) and regenerative medicine applications. in January 2021 - at the time of the death of one of the founders - it was announced that BioMagnetic Solutions had been acquired by Gamma Biosciences - itself a next-generation bioprocessing for advanced therapies. BioMagnetic Solutionsâ focus had been to provide clinicians, biomedical scientists and CAR-T Cell & Gene Therapy (CGT) product manufacturers with state-of-the-art platforms, systems and solutions that are quantum leaps ahead of existing immunomagnetic cell separation systems. This mission is driven by years of experience in innovative product development and partnering with major CGT and biopharma corporations
